294 related articles for article (PubMed ID: 33493384)
1. Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma.
Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Iwasaki A; Nabeshima K
Cancer Cytopathol; 2021 Jul; 129(7):526-536. PubMed ID: 33493384
[TBL] [Abstract][Full Text] [Related]
2. Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Iwasaki A; Nabeshima K
Mod Pathol; 2020 Feb; 33(2):235-244. PubMed ID: 31231129
[TBL] [Abstract][Full Text] [Related]
3. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
[TBL] [Abstract][Full Text] [Related]
4. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
[TBL] [Abstract][Full Text] [Related]
5. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
[TBL] [Abstract][Full Text] [Related]
7. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
[TBL] [Abstract][Full Text] [Related]
8. Update of pathological diagnosis of pleural mesothelioma using genomic-based morphological techniques, for both histological and cytological investigations.
Nabeshima K; Hamasaki M; Kinoshita Y; Matsumoto S; Sa-Ngiamwibool P
Pathol Int; 2022 Aug; 72(8):389-401. PubMed ID: 35596704
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study.
Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Kasai T; Kushitani K; Takeshima Y; Hiroshima K; Iwasaki A; Nabeshima K
Lung Cancer; 2023 Jan; 175():27-35. PubMed ID: 36442384
[TBL] [Abstract][Full Text] [Related]
10. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
[TBL] [Abstract][Full Text] [Related]
11. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
Matsumoto S; Nabeshima K; Kamei T; Hiroshima K; Kawahara K; Hata S; Marukawa K; Matsuno Y; Taguchi K; Tsujimura T
Cancer Cytopathol; 2013 Aug; 121(8):415-22. PubMed ID: 23450849
[TBL] [Abstract][Full Text] [Related]
12. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
[TBL] [Abstract][Full Text] [Related]
13. Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features.
Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kasai T; Hiroshima K; Kushitani K; Takeshima Y; Kawahara K; Iwasaki A; Nabeshima K
Ann Diagn Pathol; 2022 Oct; 60():152004. PubMed ID: 35797798
[TBL] [Abstract][Full Text] [Related]
14. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
[TBL] [Abstract][Full Text] [Related]
15. Investigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma.
Şeker NS; Tekin E; Ak G; Metintaş M; Metintaş S; Dündar E
Diagn Cytopathol; 2024 Apr; 52(4):211-216. PubMed ID: 38243885
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
Berg KB; Churg AM; Cheung S; Dacic S
Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
[TBL] [Abstract][Full Text] [Related]
17. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
18. Differential Diagnosis of Malignant Pleural Mesothelioma on Cytology: A Gene Expression Panel versus BRCA1-Associated Protein 1 and p16 Tests.
Bruno R; Alì G; Poma AM; Proietti A; Libener R; Mariani N; Niccoli C; Chella A; Ribechini A; Grosso F; Fontanini G
J Mol Diagn; 2020 Apr; 22(4):457-466. PubMed ID: 32036091
[TBL] [Abstract][Full Text] [Related]
19. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Berg KB; Dacic S; Miller C; Cheung S; Churg A
Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
[TBL] [Abstract][Full Text] [Related]
20. Morphological difference between pleural mesothelioma cells in effusion smears with either BAP1 loss or 9p21 homozygous deletion and reactive mesothelial cells without the gene alterations.
Matsumoto S; Hamasaki M; Kinoshita Y; Kamei T; Kawahara K; Nabeshima K
Pathol Int; 2019 Nov; 69(11):637-645. PubMed ID: 31580004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
